Denmark became the first country to permanently discontinue the use of AstraZeneca’s COVID-19 vaccine due to possible involvement in rare cases of blood clots.
The Danish health authority said Wednesday that, after its own assessment, the country’s vaccine implementation will continue without AstraZeneca footage, as it warned of a “real risk of serious side effects.”
DHA Director General Søren Brostrøm said: “Based on the scientific findings, our general assessment is that there is a real risk of serious side effects associated with COVID-19 use of the COVID-19 vaccine. AstraZeneca. “Therefore, we have decided to remove the vaccine from our vaccination program,” he added.
The health agency said it had agreed with the European Union’s drug regulator evaluation, quantification, evaluation that the benefits of vaccines outweigh the risks, but note that watchdog urges individual countries to consider vaccine scenarios and availability when making their statements.
Brostrøm said the epidemic is now under control in Denmark, with a large proportion of the immunized older population and those who have not been vaccinated at less risk.
“We have to weigh this against the fact that we already know the risk of serious side effects from the AstraZeneca vaccination, even if the absolute risk is mild,” he added.
People who received the first dose of AstraZeneca
The health agency said it would be invited to get another vaccine a second time.
It added that Denmark could re-use the Anglo-Swedish pharmaceutical company ‘s vaccine at a later date if the country’s situation changes.
Last week, the UK government’s vaccination advisory committee said people under 30 will be offered an alternative vaccine. It comes after the UK’s pharmaceutical regulator – the Health Care and Drug Administration (MHRA) – said the benefits outweigh the risks for most people, but the MHRA CEO Dr June Raine said for young people it is “more balanced”.
Denmark’s move is another setback to the already slow EU vaccination campaign, which was exacerbated on Tuesday after US pharmacy Johnson & Johnson
say it will delay scheduled implementation of its COVID-19 was shot through mass of 27 members due to reports of coagulation.
J&J made the decision after calling by US health authorities pause immediately about using the vaccine while they examined six serious rare cases of blood clots that have been reported in those who were vaccinated. J&J is expected to provide 55 million single-shot doses of vaccine to the EU in the second quarter.
J&J vaccines are currently only delayed, but analyst firm Airfinity warns EU vaccine rollout will be lost. two months longer than expected If the block cannot use the footage.
However, there is some good news for Europe as the EU reaches an agreement to speed up the supply of an additional 50 million doses of vaccine jointly developed by German biotechnology company BioNTech.
and US pharmaceutical company Pfizer
to promote program implementation.
Denmark’s decision could delay the country’s vaccine implementation for up to four weeks, based on previous statements by health authorities, a report by Reuters note.
The country was the first to initially suspend the use of the AstraZeneca vaccine in March over safety concerns. Last week, the EU’s pharmaceutical regulator said that “abnormal blood clots” should be listed as “very rare” the side effects of the AstraZeneca vaccine, but the claim that the benefits of the vaccine outweigh the risks.
The majority of EU countries have since started using the AstraZeneca vaccine, but a few, including Spain and Italy, have already limit The use of injections for people over 60 years old. Last month, French and German health officials restricted the use of the AstraZeneca injection to people over 55 and over 60, following concerns of abnormal clotting in some recipients.
Shares of AstraZeneca were trading 1.31% higher in London on Wednesday.
AstraZeneca acknowledged the findings from the EMA, as well as a separate review from the UK MHRA, note that they “reaffirmed the vaccine provided a high level of protection against all severity of COVID-19 and these benefits continue to outweigh the risks”.
The pharmaceutical company said it is working with global regulators to better understand individual cases, epidemiology, and mechanisms that could explain these extremely rare events. .